Evotec Receives Milestone Payment from Boehringer Ingelheim
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:EVTC) today announced that a further research milestone, leading topayments to Evotec, has been successfully achieved in its drugdiscovery collaboration with Boehringer Ingelheim. The milestone wasachieved for the identification and selection of a second compound tobe advanced into preclinical development within an existing program.This represents the sixth milestone achieved in this multi-year,multi-target collaboration and is the second compound selected forpre-development in the last twelve months.Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented:"It is great to see the scientific progress that top-class discoveryalliance projects can bring. We are jointly progressing severalprojects withBoehringer Ingelheim at this stage, so we are optimistic to seefurther product progress soon."In 2004, Evotec entered into a multi-year drug discoverycollaboration with Boehringer Ingelheim to jointly identify anddevelop preclinical development candidates for the treatment ofvarious diseases. The agreement has been expanded and extended on twooccasions since its initiation. Under the terms of the agreement,Boehringer Ingelheim has full ownership and global responsibility forclinical development, manufacturing and commercialization of thecompounds identified. In return, Evotec receives ongoing researchpayments and preclinical milestones. Furthermore, the contractprovides substantial long-term upside for Evotec through potentialpayments for successful milestone achievements during clinicaldevelopment and royalties when new drugs reach the market.Contact: Dr Werner Lanthaler, Chief Executive Officer,Evotec AG, Tel.: +49.(0)40.56081-242, werner.lanthaler(at)evotec.comForward-Looking StatementsInformation set forth in this press release contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to,statements about our expectations and assumptions concerningregulatory, clinical and business strategies, the progress of ourclinical development programs and timing of the results of ourclinical trials, strategic collaborations and management's plans,objectives and strategies. These statements are neither promises norguarantees, but are subject to a variety of risks and uncertainties,many of which are beyond our control, and which could cause actualresults to differ materially from those contemplated in theseforward-looking statements. In particular, the risks anduncertainties include, among other things: risks that productcandidates may fail in the clinic or may not be successfully marketedor manufactured; risks relating to our ability to advance thedevelopment of product candidates currently in the pipeline or inclinical trials; our inability to further identify, develop andachieve commercial success for new products and technologies;competing products may be more successful; our inability to interestpotential partners in our technologies and products; our inability toachieve commercial success for our products and technologies; ourinability to protect our intellectual property and the cost ofenforcing or defending our intellectual property rights; our failureto comply with regulations relating to our products and productcandidates, including FDA requirements; the risk that the FDA mayinterpret the results of our studies differently than we have; therisk that clinical trials may not result in marketable products; therisk that we may be unable to successfully secure regulatory approvalof and market our drug candidates; and risks of new, changing andcompetitive technologies and regulations in the U.S. andinternationally.The list of risks above is not exhaustive. Our Annual Report on Form20-F, filed with the Securities and Exchange Commission, and otherdocuments filed with, or furnished to the Securities and ExchangeCommission, contain additional factors that could impact ourbusinesses and financial performance. We expressly disclaim anyobligation or undertaking to release publicly any updates orrevisions to any such statements to reflect any change in ourexpectations or any change in events, conditions or circumstances onwhich any such statement is based.http://hugin.info/131215/R/1331372/314989.pdf --- End of Message ---Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480; ISIN: DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 29.07.2009 - 09:00 Uhr
Sprache: Deutsch
News-ID 4081
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 410 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec Receives Milestone Payment from Boehringer Ingelheim"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
